Greg L. Beilhartz

1.1k total citations
26 papers, 787 citations indexed

About

Greg L. Beilhartz is a scholar working on Infectious Diseases, Molecular Biology and Virology. According to data from OpenAlex, Greg L. Beilhartz has authored 26 papers receiving a total of 787 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 14 papers in Molecular Biology and 11 papers in Virology. Recurrent topics in Greg L. Beilhartz's work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers) and Toxin Mechanisms and Immunotoxins (10 papers). Greg L. Beilhartz is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers) and Toxin Mechanisms and Immunotoxins (10 papers). Greg L. Beilhartz collaborates with scholars based in Canada, United States and Netherlands. Greg L. Beilhartz's co-authors include Matthias Götte, Roman A. Melnyk, Anick Auger, John Tam, Seiji N. Sugiman‐Marangos, Suzanne McCormick, Michaela Wendeler, Jason W. Rausch, Pulkit Gupta and Egor P. Tchesnokov and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Greg L. Beilhartz

26 papers receiving 778 citations

Peers

Countries citing papers authored by Greg L. Beilhartz

Since Specialization

Citations

This map shows the geographic impact of Greg L. Beilhartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg L. Beilhartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg L. Beilhartz more than expected).

Fields of papers citing papers by Greg L. Beilhartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg L. Beilhartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg L. Beilhartz. The network helps show where Greg L. Beilhartz may publish in the future.

Co-authorship network of co-authors of Greg L. Beilhartz

This figure shows the co-authorship network connecting the top 25 collaborators of Greg L. Beilhartz. A scholar is included among the top collaborators of Greg L. Beilhartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg L. Beilhartz. Greg L. Beilhartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	De novo design of potent inhibitors of clostridial family toxins 2025 ·Proceedings of the National Academy of Sciences ·Robert J. Ragotte, (unknown), John Kit Chung Tam, (unknown), Jacob M. Berman, (unknown), Connor Weidle, (unknown), (unknown), Greg L. Beilhartz, (unknown), Andrew J. Borst, Brian Coventry, Xinru Wang, John L. Rubinstein, Mike Tyers, Daniel Schramek, Roman A. Melnyk, David Baker	1
2	An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies 2024 ·EMBO Molecular Medicine ·(unknown), Seiji N. Sugiman‐Marangos, Greg L. Beilhartz, (unknown), Mikko Taipale, Roman A. Melnyk	2
3	Abstract 1919: Activity and affinity tuning next-generation immunotoxins for targeted therapy 2024 ·Cancer Research ·(unknown), Greg L. Beilhartz, (unknown), Roman A. Melnyk	1
4	bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA) 2020 ·Proceedings of the National Academy of Sciences ·Shuhui Lim, (unknown), (unknown), (unknown), Shih Chieh Chang, Simon Ng, Greg L. Beilhartz, Roman A. Melnyk, Charles W. Johannes, Christopher J. Brown, David P. Lane, Brian Henry, Anthony W. Partridge	107
5	Attenuated diphtheria toxin mediates siRNA delivery 2020 ·Science Advances ·(unknown), Laura J. Smith, Greg L. Beilhartz, (unknown), (unknown), Roman A. Melnyk, Molly S. Shoichet	18
6	An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth 2020 ·Proceedings of the National Academy of Sciences ·(unknown), Greg L. Beilhartz, (unknown), Marco Biancucci, (unknown), David Gius, Roman A. Melnyk, K.J.F. Satchell	28
7	Recognition of Semaphorin Proteins by P. sordellii Lethal Toxin Reveals Principles of Receptor Specificity in Clostridial Toxins 2020 ·Cell ·Hunsang Lee, Greg L. Beilhartz, Iga Kucharska, Swetha Raman, Hong Cui, Mandy Hiu Yi Lam, (unknown), John L. Rubinstein, Daniel Schramek, Jean‐Philippe Julien, Roman A. Melnyk, Mikko Taipale	32
8	Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota 2018 ·Nature Communications ·John Tam, Therwa Hamza, Bing Ma, Kevin Chen, Greg L. Beilhartz, Jacques Ravel, Hanping Feng, Roman A. Melnyk	46
9	Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target Cells 2018 ·Molecular Pharmaceutics ·(unknown), Xiaobai Xu, Weixian Min, Seiji N. Sugiman‐Marangos, Greg L. Beilhartz, Jarrett Adams, Sachdev S. Sidhu, Eyal Grunebaum, Roman A. Melnyk	13
10	Repurposing bacterial toxins for intracellular delivery of therapeutic proteins 2017 ·Biochemical Pharmacology ·Greg L. Beilhartz, Seiji N. Sugiman‐Marangos, Roman A. Melnyk	38
11	Small Molecule Inhibitors of Clostridium difficile Toxin B-Induced Cellular Damage 2015 ·Chemistry & Biology ·John Tam, Greg L. Beilhartz, Anick Auger, Pulkit Gupta, Alex G. Therien, Roman A. Melnyk	57
12	Inhibition of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase by GSK5750 Correlates with Slow Enzyme-Inhibitor Dissociation 2014 ·Journal of Biological Chemistry ·Greg L. Beilhartz, (unknown), Brian A. Johns, Felix Deanda, Peter Gerondelis, Matthias Götte	25
13	Derivatives of Mesoxalic Acid Block Translocation of HIV-1 Reverse Transcriptase 2014 ·Journal of Biological Chemistry ·Jean Bernatchez, R. J. Paul, Egor P. Tchesnokov, (unknown), Greg L. Beilhartz, Albert M. Berghuis, (unknown), Lianhai Li, Anick Auger, Roman A. Melnyk, Jay A. Grobler, Michael D. Miller, Daria J. Hazuda, Sidney M. Hecht, Matthias Götte	14
14	Impact of Primer-induced Conformational Dynamics of HIV-1 Reverse Transcriptase on Polymerase Translocation and Inhibition 2011 ·Journal of Biological Chemistry ·Anick Auger, Greg L. Beilhartz, (unknown), Elizabeth Cauchon, Jean‐Pierre Falgueyret, Jay A. Grobler, Maryam Ehteshami, Matthias Götte, Roman A. Melnyk	2
15	N348I in HIV-1 Reverse Transcriptase Can Counteract the Nevirapine-mediated Bias toward RNase H Cleavage during Plus-strand Initiation 2010 ·Journal of Biological Chemistry ·Mia J. Biondi, Greg L. Beilhartz, Suzanne McCormick, Matthias Götte	23
16	Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFκB in differentiating NB4 leukemia cells 2010 ·Experimental Cell Research ·(unknown), Greg L. Beilhartz, (unknown), Cynthia L. Richard, (unknown), (unknown), (unknown), Marc G. Coppolino, Mary C. Farach‐Carson, Ilka Nemere, Kelly A. Meckling	49
17	Structure-Activity Analysis of Vinylogous Urea Inhibitors of Human Immunodeficiency Virus-Encoded Ribonuclease H 2010 ·Antimicrobial Agents and Chemotherapy ·Suhman Chung, Michaela Wendeler, Jason W. Rausch, Greg L. Beilhartz, Matthias Götte, Barry R. O’Keefe, Alun Bermingham, John A. Beutler, Shixin Liu, Xiaowei Zhuang, Stuart F.J. Le Grice	42
18	HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors 2010 ·Viruses ·Greg L. Beilhartz, Matthias Götte	63
19	HIV-1 Reverse Transcriptase Can Simultaneously Engage Its DNA/RNA Substrate at Both DNA Polymerase and RNase H Active Sites: Implications for RNase H Inhibition 2009 ·Journal of Molecular Biology ·Greg L. Beilhartz, Michaela Wendeler, Noel Baichoo, Jason W. Rausch, Stuart Le Grice, Matthias Götte	51
20	Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms 2008 ·Journal of Biological Chemistry ·Maryam Ehteshami, Greg L. Beilhartz, (unknown), Egor P. Tchesnokov, Suzanne McCormick, Brian Wynhoven, P. Richard Harrigan, Matthias Götte	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact